
In the STEP trials, once‐weekly subcutaneous semaglutide 2.4 mg plus lifestyle intervention reduced body weight and improved cardiometabolic parameters in adults with obesity. Cardiometabolic Disease Staging risk assessment suggests that once‐weekly semaglutide 2.4 mg may substantially lower 10‐year T2D risk in people with overweight or obesity.
Like
Save
Share